Theratechnologies
Theratechnologies is a Canada-headquartered commercial-stage biopharmaceutical company that markets three FDA-approved HIV drugs in the United States—Trogarzo, EGRIFTA WR, and EGRIFTA SV—targeting multidrug-resistant HIV-1 and HIV-associated lipodystrophy through specialty pharmacy distribution, and was acquired by Future Pak in September 2025.
- Company typePublic
- Founded1993
- HeadquartersMontréal, Canada
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Theratechnologies does
Theratechnologies is a commercial-stage biopharmaceutical company headquartered in Montreal, Quebec, that develops and markets specialty prescription drugs focused on unmet medical needs in HIV. Originally founded in 1993, the company transitioned from an outsourced model to in-house commercial operations in 2014 and currently markets three FDA-approved prescription products in the United States—Trogarzo (ibalizumab-uiyk), EGRIFTA WR (tesamorelin F8) approved March 2025, and EGRIFTA SV (tesamorelin F4)—together with Mytesi in its HIV portfolio. The company also holds licensing rights from Ionis to olezarsen and donidalorsen for potential future commercialization in rare diseases.
EGRIFTA WR is patent-protected in the United States until 2033 and represents the only FDA-approved treatment for excess abdominal fat in HIV-associated lipodystrophy; its predecessor EGRIFTA SV is being systematically transitioned out by the company. Trogarzo, a long-acting monoclonal antibody that binds CD4 T-cell domain 2 to block viral entry, was the first new HIV drug class approved in more than ten years and the first long-acting HIV treatment cleared by the FDA, and received FDA approval for IV push administration in October 2022. Commercial operations are concentrated in the United States, where field-sales teams target HIV-treating physicians, McKesson serves as primary distributor, and dispensing runs through a specialty pharmacy network supported by the Thera Patient Support patient-navigator program.
Theratechnologies generated $19.0 million in Q1 2025 revenue (+17.2% YoY), with full-year 2025 pre-acquisition guidance of $80–83 million later withdrawn. The capital structure was materially reshaped first by an October 2023 US$25 million public offering plus concurrent Investissement Québec private placement, and then by up to $75 million in new credit facilities from TD Bank and Investissement Québec in December 2024. In September 2025, CB Biotechnology, an affiliate of Future Pak, completed an acquisition with US$254 million total consideration, taking the company private and delisting it from TSX and NASDAQ.
Theratechnologies firmographics
Firmographics- Name
- Theratechnologies
- Legal name
- Theratechnologies Inc.
- Website
- https://theratech.com
- Company type
- Public
- Founded year
- 1993
- Operating status
- Acquired
- Headcount range
- 51–100 employees
- Short description
- Theratechnologies is a Canada-headquartered commercial-stage biopharmaceutical company that markets three FDA-approved HIV drugs in the United States—Trogarzo, EGRIFTA WR, and EGRIFTA SV—targeting multidrug-resistant HIV-1 and HIV-associated lipodystrophy through specialty pharmacy distribution, and was acquired by Future Pak in September 2025.
- Ownership category
- akta.pro rank
Theratechnologies industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)
Keywords
Where Theratechnologies is headquartered
LocationHeadquarters
- HQ city
- Montréal
- HQ country
- Canada
- HQ region
- North America
Offices2 records
Markets served
Theratechnologies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Others
Revenue model
- Product sales (EGRIFTA SV/WR and Trogarzo): Theratechnologies generates revenue through the sale of prescription pharmaceutical products. EGRIFTA SV net sales were $13.9M in Q1 2025 (44.8% YoY increase) and $11.1M in Q2 2025. Trogarzo net sales were $5.2M in Q1 2025 (22.4% decrease) and $6.6M in Q2 2025 (13.4% increase). Q1 2025 total revenue was $19.0M representing 17% growth YoY. Full year 2025 guidance was $80-83M revenue.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
Theratechnologies product offering
Product offeringCore offering
Theratechnologies is a commercial-stage biopharmaceutical company that develops and commercializes FDA-approved prescription therapeutics for people living with HIV. Its marketed portfolio includes Trogarzo (ibalizumab-uiyk) for multi-drug resistant HIV-1, EGRIFTA SV and EGRIFTA WR (tesamorelin) for HIV-associated lipodystrophy, and Mytesi (crofelemer) for HIV-related non-infectious diarrhea. The company engages in proprietary drug discovery, formulation science, and specialty commercialization focused on underserved HIV treatment niches.
Product overview
Theratechnologies is a commercial-stage biopharmaceutical company that commercializes three FDA-approved prescription products for people with HIV in the United States: Trogarzo® (ibalizumab-uiyk), a long-acting monoclonal antibody for heavily treatment-experienced patients with multidrug resistant HIV; EGRIFTA WR™ (tesamorelin F8), the newest formulation approved in March 2025 for reducing excess visceral abdominal fat in HIV patients with lipodystrophy; and EGRIFTA SV® (tesamorelin F4), the daily-reconstituted predecessor formulation being gradually replaced by EGRIFTA WR™. The company also markets Mytesi® as part of its HIV portfolio. The products focus on addressing unmet medical needs in HIV treatment and HIV-associated conditions like lipodystrophy.
Differentiator
Problem solved
Functional benefit
Brands
- Trogarzo: Long-acting monoclonal antibody for treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1
- EGRIFTA SV
- EGRIFTA WR
- Mytesi
Products and services
- Trogarzo (ibalizumab-uiyk)
Quantifiable outcome
- EGRIFTA SV sales increased 44.8% YoY in Q1 2025 to $13.9M
- +3 more outcomes
Companies that use Theratechnologies
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
Theratechnologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Theratechnologies partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered flagship and core.
- Future Pak / CB BiotechnologyflagshipFuture Pak (through its affiliate CB Biotechnology) completed acquisition of Theratechnologies for US$254 million total consideration on September 25, 2025. Future Pak is a privately held contract manufacturer, packager and distributor of pharmaceutical and nutraceutical products founded in 1977 and headquartered in Wixom, Michigan.
- McKessoncoreMcKesson serves as the primary wholesale distributor for Theratechnologies' pharmaceutical products (EGRIFTA SV/WR and Trogarzo) in the United States. Distribution resumed in February 2025 following supply disruption resolution.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
Theratechnologies competitors and assessment
Company assessmentDirect peers
- ViiV Healthcare: ViiV Healthcare is the leading dedicated HIV specialty pharmaceutical company (owned by GSK, Pfizer and Shionogi). It directly competes with Theratechnologies in HIV therapeutics and long-acting HIV treatment development, making it the closest comparable in category, patient base, and commercial model.
- TaiMed Biologics: TaiMed Biologics is the originator/developer of ibalizumab (Trogarzo) and a specialty HIV-focused biotechnology company. It is a direct peer in HIV drug development with a closely aligned technology base and target indication.
Emerging players
- Nabriva Therapeutics: Nabriva is a small specialty anti-infectives company focused on niche infectious-disease indications. While not a direct HIV peer, its specialty infectious-disease model and small-scale commercial footprint are operationally comparable.
- Brii Biosciences: Brii Biosciences is a clinical-stage infectious-disease biopharma focused on HIV cure and treatment in partnership with major players. It represents an emerging player overlapping with Theratechnologies' HIV therapeutic focus.
Broad incumbents
- Bausch Health: Bausch Health operates a specialty pharmaceutical division with focus areas including infectious disease and rare disorders. Its specialty pharma model and broad portfolio are comparable to Theratechnologies' commercial-stage specialty pharma positioning.
- Johnson & Johnson (Janssen): Janssen markets long-acting HIV regimens (cabotegravir/rilpivirine) that overlap with the patient segments addressed by Trogarzo. As a large incumbent in infectious disease and HIV, it is a critical competitor to Theratechnologies' niche HIV franchise.
- Ionis Pharmaceuticals: Ionis is Theratechnologies' licensor for olezarsen and donidalorsen and operates as a specialty RNA-targeting biopharmaceutical company. It is comparable in therapeutic focus (rare/specialty diseases) and as a development partner shaping Theratechnologies' pipeline.
- Merck & Co. Merck is a major HIV franchise participant (Dovato/islatravir programs, doravirine) and a broad biopharmaceutical incumbent. Its investment in long-acting HIV and infectious disease therapies places it in overlapping competitive and licensing territory with Theratechnologies.
- BioMarin Pharmaceutical: BioMarin is a rare-disease specialty biopharmaceutical company commercializing drugs through specialty pharmacy channels and physician networks. Its operating model—small patient populations, specialty distribution, and high-touch patient services—mirrors Theratechnologies' U.S. commercial approach.
- Gilead Sciences: Gilead is the dominant broad HIV franchise (Biktarvy, Descovy, Sunlenca) and a major infectious-disease biopharmaceutical incumbent. Although broader than Theratechnologies, it competes in the same patient population and shapes the standard-of-care regimen against which EGRIFTA and Trogarzo are positioned.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Theratechnologies social profiles
Digital presenceTheratechnologies compliance and trust
Trust signalCompliance1 record
Theratechnologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
Theratechnologies leadership team
Management profileNumber of profiles
Profiles11 records
Theratechnologies subsidiaries and ownership
Company hierarchySubsidiaries2 records
Theratechnologies funding detail
Funding detailFunding overview
Funding rounds7 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Theratechnologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Theratechnologies
What does Theratechnologies do?
Theratechnologies is a commercial-stage biopharmaceutical company that develops and commercializes FDA-approved prescription therapeutics for people living with HIV. Its marketed portfolio includes Trogarzo (ibalizumab-uiyk) for multi-drug resistant HIV-1, EGRIFTA SV and EGRIFTA WR (tesamorelin) for HIV-associated lipodystrophy, and Mytesi (crofelemer) for HIV-related non-infectious diarrhea. The company engages in proprietary drug discovery, formulation science, and specialty commercialization focused on underserved HIV treatment niches.
Is Theratechnologies a public or private company?
Theratechnologies is a public company. It is classified as corporate owned and is currently acquired.
When was Theratechnologies founded?
Theratechnologies was founded in 1993. It employs 51 to 100 people.
Where is Theratechnologies based?
Theratechnologies is headquartered in Montréal, Canada, in the North America region.
How does Theratechnologies make money?
One revenue line is on record: product sales (EGRIFTA SV/WR and Trogarzo).
Who are Theratechnologies's main competitors?
Direct peers on record are ViiV Healthcare and TaiMed Biologics. Emerging players are Nabriva Therapeutics and Brii Biosciences. Broad incumbents are Bausch Health, Johnson & Johnson (Janssen), Ionis Pharmaceuticals, Merck & Co., BioMarin Pharmaceutical and Gilead Sciences.
Does Theratechnologies have an API?
No public API is recorded for Theratechnologies.
What industry is Theratechnologies in?
Theratechnologies's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.